MedTrace Logo

Metformin ER 750 mg Tablets, Fasting

NCT00834743 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2024-08-19

Study results available
· View outcomes & findings →

Summary

The objective of this study is to compare the rate and extent of absorption of metformin from a test formulation of Metformin ER 750 mg Tablets versus the reference Glucophage® XR 750 mg Tablets under fasting conditions.

Conditions

  • Healthy

Interventions

DRUG

Glucophage® XR 750 mg Tablets

1 x 750 mg, single-dose fasting

DRUG

Metformin ER 750 mg Tablets

1 x 750 mg, single-dose fasting

Sponsors & Collaborators

  • Teva Pharmaceuticals USA

    lead INDUSTRY

Principal Investigators

  • Paul Y. Tam, M.D. · Biovail Contract Research

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-08-31
Primary Completion
2003-08-31
Completion
2003-08-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00834743 on ClinicalTrials.gov